UNSPSC 51385402: Diclonixin

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C12H8Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 357591W853, chemically known as 2-(2,3-dichloroanilino)-nicotinic acid. but generally known as diclonixin, which bears US NIH Compound Identifier 208833. European Medicines Agency schedules Diclonixin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07097MIG.

UNSPSC 51385402 Diclonixin is a Commodity code that designates a single pharmaceutical product line. State and local procurement under this code encompasses the purchase of naloxone, opioid-antagonist medications, and related drug deactivation systems for community health programs, emergency medical services, and public health initiatives. Recent solicitations show state and local governments buying naloxone and safe drug deactivation systems in bulk quantities, with deliveries structured on quarterly or as-needed schedules to health departments, county health buildings, and pharmacy benefit programs. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions and state facilities.

Recent activity appears concentrated in Florida and Minnesota, with Texas also represented through a state HHS market-intelligence exercise. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, requiring quarterly delivery to the Seminole County Community Health Building in Sanford and including E-Verify compliance and drug-free workplace certification. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 in January 2026 with a March 26, 2026 response deadline to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with awarded vendors required to supply through three authorized wholesalers and maintain cGMP and Drug Supply Chain Security Act compliance. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 as a preliminary market-intelligence gathering phase regarding direct-to-manufacturer prescription programs for state pharmacy benefits.